0000899243-21-030231.txt : 20210727 0000899243-21-030231.hdr.sgml : 20210727 20210727215152 ACCESSION NUMBER: 0000899243-21-030231 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210727 FILED AS OF DATE: 20210727 DATE AS OF CHANGE: 20210727 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRANDELL KEITH CENTRAL INDEX KEY: 0001219039 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40676 FILM NUMBER: 211119650 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DA32 Life Science Tech Acquisition Corp. CENTRAL INDEX KEY: 0001863294 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 863352988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 551-1600 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-07-27 0 0001863294 DA32 Life Science Tech Acquisition Corp. DALS 0001219039 CRANDELL KEITH DA32 LIFE SCIENCE TECH ACQUISITION CORP 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 100100 1 0 1 0 Class B Common Stock Class A Common Stock 30000 D Class B Common Stock Class A Common Stock 5166250 I Through DA32 Sponsor LLC The Reporting Person directly owns 30,000 shares of Class B Common Stock, which are convertible into shares of Class A Common Stock as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-257679) and have no expiration date. DA32 Sponsor LLC ("Sponsor") is the record holder of the securities reported herein. As a managing member of Sponsor, ARCH Venture Fund XI, L.P. ("AVF") may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVF, ARCH Venture Partners XI, L.P. ("AVP LP") may be deemed to beneficially own the securities owned directly by Sponsor. As the sole general partner of AVP LP, ARCH Venture Partners XI, LLC ("AVP LLC") may be deemed to beneficially own securities owned directly by Sponsor. As the members of the investment committee, each of Kristina Burow, Robert Nelsen, Keith Crandell and Steven Gillis may be deemed to beneficially own securities owned directly by Sponsor. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein. The shares of Class B Common Stock are convertible for shares of the Issuer's Class A Common Stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date. The shares of Class B Common Stock beneficially owned by the Reporting Person include up to 750,000 shares of Class B Common Stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of Class A Common Stock, as described in the Registration Statement. See Exhibit 24.1 - Power of Attorney. /s/ Henrikki Harsu, Attorney-in-Fact 2021-07-27 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                                   POWER OF ATTORNEY

        The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:

        1.     prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and

        2.     sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.

        A copy of this power of attorney shall be filed with the SEC.  The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.

        The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.

Dated: June 29, 2021

                                        /s/ Keith L. Crandell
                                        -------------------------------
                                        Keith L. Crandell